Indian pharma faces greater U.S. scrutiny amid more trade

09/13/2013 | Reuters

The U.S. FDA's increased on-the-ground oversight of drugmakers in India shows the country's increasing importance as a U.S. supplier. "As more trade happens, as more drugs are approved and applications are submitted we will have to inspect more. The problems we have seen with some companies are why we choose to make quality as one of our highest priorities," said Altaf Lal, the FDA office director for India. Investors could be fazed by frequent enforcement measures and inquiries to Indian drugmakers.

View Full Article in:

Reuters

Published in Briefs: